Editorial |

Molecular Prognostic Testing in Uveal Melanoma:  Has It Finally Come of Age?

J. William Harbour, MD
Arch Ophthalmol. 2007;125(8):1122-1123. doi:10.1001/archopht.125.8.1122.
Text Size: A A A
Published online


Uveal melanoma continues to be one of the deadliest diseases encountered in ophthalmology, with many patients dying of metastatic disease. Despite improvements in diagnosis and treatment of the primary tumor, there has not been a corresponding improvement in survival.1 This inability to prevent metastatic disease appears to be due to clinically undetectable micrometastasis occurring before the primary tumor is treated and becoming clinically manifest only months to years later.2 As a result, survival from uveal melanoma is unlikely to improve in the foreseeable future solely through incremental improvements in managing the primary tumor. Concurrently, there are no existing therapies, or new ones on the horizon, with a reasonable prospect of improving survival in patients with advanced metastatic melanoma, so waiting for overt metastatic disease to manifest before initiating systemic therapy will continue to be of limited value. If patients with uveal melanoma are to live longer, new approaches will be required to identify high-risk patients and intervene earlier to delay or prevent metastatic disease.

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview





Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles
Congenital uveal malignant melanoma. J AAPOS 2014;18(2):199-201.